Nuclear factor erythroid 2-related factor 2 (NRF2) is a key transcription factor that protects cells from oxidative stress and cell damage caused by environmental stressors, including ionizing radiations (IRs). Under normal conditions, NRF2 is kept inactive in the cytoplasm by its interaction with Kelch-like ECH-associated protein 1 (Keap1), an E3 ubiquitin ligase which drives NRF2 degradation [1]. Under oxidative stress, the interaction between Keap1 and NRF2 is impaired, allowing NRF2 to stabilize and translocate to the nucleus to activate target gene promoters with antioxidant response elements (ARE) whose encoded proteins help protect cells from oxidative stress [2, 3]. In tumour, NRF2 plays a double role. During the first phases of carcinogenesis its activation can be mainly cytoprotective by suppressing oxidative stress and tumor-promoting inflammation, both responsible of increased DNA mutations. On the other hand, NRF2 hyperactivation in many cancers, by different mechanisms, may support tumorigenesis, resistance to chemo- and radiotherapy, and enhanced cancer cell survival by strengthening antioxidant defenses and detoxification pathways that counteract cell death induced by oxidative stress and increase genetic instability [4]. Such dysregulation supports cancer progression, metastasis, and resistance to therapies, making NRF2 a potential attractive therapeutic target to enhance the efficacy of the current cancer treatments [5].

IRs, including those used in medical diagnostic and cancer therapy, can cause oxidative stress and DNA damage [6]. In diagnostic imaging, low doses of IR may increase cancer risk over time. The presence of oxidatively-induced clustered DNA lesions (OCDLs) challenges the linear no-threshold (LNT) model, as even low radiation doses can cause complex, hard-to-repair damage. Due to their high biological impact, OCDLs may disproportionately drive mutations and cancer, suggesting low doses could be more harmful than previously assumed [7, 8, 9, 10]. In radiotherapy, higher doses of IR target cancer cells but can also damage healthy tissues, leading to DNA breaks, inflammation, and eventually secondary cancers [11]. IR can directly interact with DNA causing single-strand or double-strand breaks, or induce indirect DNA damage through water ionization and reactive oxygen species (ROS) generation, which further harm cellular components [11, 12]. Emerging research now shows that NRF2-mediated transcription can protect cells and tissues from the pathogenic consequences of hydroxyl radicals that are directly generated by IR as well as of the hydrogen peroxide and superoxide that are generated as a secondary consequence of irradiation which can have an impact on both normal and cancer tissues.

In this review, we explore the role of NRF2 in the response to the damage caused by IR, with a focus on its effects in clinical diagnostic and radiotherapy.

NRF2 is a transcription factor encoded by the NFE2L2 gene and belonging to the cap “n” collar subfamily of basic-region leucine zipper proteins [13]. It has a central role in cytoprotection by reducing oxidative stress and maintaining redox homeostasis. NRF2 regulates the expression of numerous target genes critical for cellular processes like detoxification and cytoprotection, particularly those involved in protecting against oxidative stress and supporting cellular homeostasis including heme oxygenase 1 (HO-1), Aldo-keto reductase (AKR), NADPH quinone oxidoreductase 1 (NQO-1), superoxide dismutase (SOD), catalase, multidrug resistance-associated protein (MRP), and ATP-binding cassette (ABC) transporters [14]. Additionally, it exerts anti-inflammatory activity by regulating a variety of downstream genes such as Interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-$\alpha$), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX2), and plays a vital role in DNA repair mechanisms encoding DNA repair proteins and enzymes involved in non-homologous end joining (NHEJ), homologous recombination (HR), base excision repair (BER), and nucleotide excision repair (NER) [15, 16, 17, 18]. Additionally, NRF2 regulates genes linked to autophagy, apoptosis, and metabolism, further supporting its role in cellular protection and stress adaptation (Table 1) [16, 19, 20].

2.1 NRF2 Activation

Under normal conditions, NRF2 is retained in the cytoplasm through its interaction with two proteins: Keap1, an actin cytoskeleton-associated protein with 25 cysteines that function as “sensors” for the NFR2/Keap1 regulatory system [1], and Cullin 3 (CUL3), a scaffold protein that is part of the E3 ubiquitin ligase complex [21]. This complex mediates NRF2 ubiquitination, which is then targeted for proteasomal degradation (Fig. 1A, left side). As a reaction to oxidative stress, cysteines 273 and 288 on Keap1 are modified by reactive oxygen species and electrophiles leading to protein conformational changes. As a result, the Keap1-CUL3-NRF2 ubiquitination system is impaired, hindering the ubiquitination of NRF2 and causing its accumulation in the cytoplasm [22]. Afterward, NRF2 translocates to the nucleus, where it forms a heterodimer with one of the small musculoaponeurotic fibrosarcoma (MAF) proteins and binds to antioxidant response elements (AREs) in the promoter regions of target genes (Fig. 1A, right side) [4]. Besides this canonical activation, NRF2 can be activated via a non-canonical mechanism by Ser349 phosphorylated p62/sequestome 1 (SQSTM1) (p-STGE), a key autophagyc adaptor that interacts with Keap1, inducing its degradation through autophagy, thereby triggering NRF2 stabilization and activation (Fig. 1B) [23]. Additionally, NRF2 activation can be regulated by a feedback mechanism involving (BTB Domain and CNC Homolog 1) BACH1 [24], a physiological repressor of NRF2 that is itself stabilized by NRF2 (Fig. 1C) [25, 26]. Both NRF2 and BACH1 associate to form a heterodimer with MAF proteins and bind to ARE sites in the promoters of cytoprotective genes. Under basal conditions or low oxidative stress, MAF-BACH1 heterodimers occupy these ARE sites, acting as transcriptional repressors (Fig. 1C, left side). As a reaction to oxidative stress, NRF2 is activated and its increased availability and affinity for AREs displace the BACH1/MAF complex from the ARE sites leading to activation of protective gene expression [27]. Notably, NRF2 activation can also induce BACH1 expression via ARE sites in its promoter, establishing a negative feedback circuit that limits the duration and intensity of the NRF2 response (Fig. 1C, right side) [28].

Fig. 1.

Nuclear factor erythroid 2-related factor 2 (NRF2) activation. (A) Under normal conditions, NRF2 is retained in the cytoplasm through its interaction with Keap1 and Cullin3 (CUL3) that allows proteasomal ubiquitination and degradation. During oxidative stress, the Keap1-CUL3-NRF2 ubiquitination system is disrupted, allowing NRF2 to accumulate in the cytoplasm and translocate to the nucleus. In the nucleus, NRF2 forms a heterodimer with MAF proteins and binds to antioxidant response elements (AREs) in the promoter regions of target genes promoting transcription (canonical activation). (B) In a non-canonical activation pathway, p-STGE (Ser349 phosphorylated p62 motif) competes with NRF2 for Keap1 binding, leading to the dissociation of NRF2. This allows NRF2 to accumulate in the cytoplasm, translocate to the nucleus, bind to target genes, and promote transcription. (C) Under basal conditions, BACH1 (BTB Domain and CNC Homolog 1) occupies ARE sites, repressing transcription of target genes. Following oxidative stress, NRF2 is activated and displaces the BACH1/MAF complex from the ARE sites, activating the expression of protective gene, including BACH1, creating a negative feedback loop (dotted arrow). ROS, reactive oxygen species; IR, ionizing radiation.

2.2 The Dual Role of NRF2 in Cancer

NRF2 plays a complex and dual role in cancer, influencing different stages of tumorigenesis in either protective or pro-tumorigenic ways and acting on both healthy and tumor cells [4, 29]. Despite the progress in the knowledge of NRF2 in recent years, there is still no clear consensus on its exact role during carcinogenesis [30, 31]. In normal cells, including the very early stages of neoplastic transformation, NRF2, through the expression of antioxidant and detoxifying enzymes, protects the cells against oxidative stress and cellular damage and therefore blocks carcinogenesis [32] (Fig. 2, upper panel). However, a tumor-promoting role for NRF2 in cancer initiation has been reported linked, for instance, to its protection against redox stress in cells with mutations in kirsten rat sarcoma viral oncogene homolog (KRAS) and/or serine/threonine kinase 11 (STK11) [33]. In the subsequent stages of tumor promotion and in the neoplastic progression, the role of NRF2 shifts, as its persistent activation becomes a key driver of cancer cell survival and proliferation and resistance to cancer treatments, often in an interplay with oncogenic pathways such as signal transducer and activator of transcription 3 (STAT3) or mutant p53 [34, 35] (Fig. 2, lower panel). By upregulating a variety of detoxification and antioxidant genes, NRF2 supports the adaptation of tumor cells to the harsh tumor microenvironment, providing resistance to cytotoxic effects of chemo- and radio-therapy in many types of tumors including breast, lung, pancreatic, head and neck, colon, etc., [36, 37, 38, 39, 40, 41, 42, 43, 44]. NRF2 activation also protects cancer cells from ferroptosis, an iron-dependent and lipid peroxidation-driven cell death cascade, occurring when there is an imbalance of redox homeostasis in the cell [45]. NRF2 upregulates multiple genes that block ferroptosis such as SLC7A11 (xCT) or glutamate-cysteine ligase (GCLC)/glutamate-cysteine ligase modifier (GCLM), modulates iron metabolism genes to limit iron-driven ROS, and limit the availability of polyunsaturated fatty acids (PUFAs)—the main substrates for lipid peroxidation [46]. NRF2 also protects cells from apoptosis, allowing cancer cells to escape death especially the one induced by anticancer treatments [20, 47]. Furthermore, NRF2 has been implicated in promoting metastasis, partly by facilitating epithelial-to-mesenchymal transition (EMT), which enhances the invasive capacity of tumor cells [26, 48, 49, 50]. Thus, while NRF2 initially serves as a protective response to cellular oxidative stress to block carcinogenesis, its chronic activation in established cancers contributes to tumor growth, metastasis, and therapy resistance. In summary, this dual role makes NRF2 a challenging molecular target for therapeutic intervention in cancer [30], as its inhibition may on one hand improve cancer cell response to cytotoxic cancer treatments [51, 52, 53], but, on the other hand, may impair its normal protective functions in healthy cells contributing to carcinogenesis. Therefore, more precise targeting strategies need to be taken in consideration [31, 54].

Fig. 2.

Dual role of NRF2 in both normal and cancer cells. In normal cells or early stage carcinogenesis, NRF2 acts as a protector against oxidative stress-induced cellular damage. In established tumors, NRF2 can acquire a pro-tumorigenic function. Its persistent activation can support tumor growth and proliferation by inducing the expression of antioxidant and detoxifying enzymes. “$\uparrow$” means increase.

IR interacts with biological tissues generating either direct or indirect effects [12, 55]. The extent of DNA damage caused by IR depends primarily on the ionization density, absorbed dose, dose rate, and linear energy transfer (LET) [56]. The high linear energy transfer (LET) IRs, i.e., alpha-particles and heavy ions, induce damage mostly by direct action, whereas the low LET IR, i.e., X-Rays and gamma-rays, by indirect one. Direct effects occur by the direct ionization and excitation of DNA molecules, which disrupt the molecular structure. The direct interaction can result in DNA single-strand breaks (SSBs) or double-strand breaks (DSBs) which, if not properly repaired, can result in mutations, genomic instability, or cellular death [57]. Indirect effects, in contrast, occur through the radiolysis of water, leading to the formation of highly reactive species like hydroxyl radicals (OH•), hydrogen peroxide (H2O2), and superoxide anion (O2•-). These reactive oxygen species (ROS) can cause damage to cellular components, including DNA, proteins, and lipids. In addition, reactive nitrogen species (RNS) such as nitric oxide (NO•) and peroxynitrite (ONOO-) may form, contributing to further cellular damage. This cascade of oxidative and nitrosative stress can result in DNA mutations, cell death, and in a broad range of biological effects, from immediate tissue damage to long-term outcomes such as cancer development [58].

The most severe damage resulting from IR exposure is DNA DSBs, which is mainly repaired through non-homologous end joining (NHEJ) and homologous recombination (HR) mechanisms [59, 60, 61, 62]. These repair processes rely on a network of factors that detect, repair, and maintain genomic stability, ensuring the cell can recover from IR-induced DNA injury or, if necessary, trigger appropriate cell death to prevent genomic instability. Key sensors like ataxia telangiectasia mutated (ATM) and ATM and Rad3-related (ATR) detect DSBs and SSBs, respectively, and initiate a signaling cascade involving checkpoint proteins like checkpoint kinase 1 (CHK1) and CHK2 to arrest the cell cycle and allow DNA damage repair [63, 64]. If the damage is irreparable, oncosuppressor p53 triggers permanent cell cycle arrest by replicative senescence or cell death by apoptosis [65]. Additionally, proteins such as breast cancer gene 1 (BRCA1) and BRCA2 play crucial roles in DNA repair and checkpoint regulation, particularly in the HR pathway [66].

IR used in clinical setting have distinct effects depending on whether they are employed for diagnosis purposes or radiotherapy and also present risks because of their ability to induce molecular and cellular damage, as seen above [67]. In diagnostic applications, IR are primarily used to create detailed scans of internal bodily organs. Techniques such as X-rays, computed tomography (CT), mammography and nuclear medicine aid in the diagnosis of various medical conditions. X-rays are commonly employed to obtain images of bones, detect fractures, and diagnose lung conditions like tuberculosis [68]. CT scans, which involve a series of X-ray images combined to create detailed cross-sectional views, provide comprehensive information on complex issues such as tumors, internal bleeding, and organ diseases [69]. Mammography, is a critical imaging modality in the screening of breast carcinoma, utilizing IR to obtain detailed breast tissue images that can identify nodules, calcifications, or other abnormalities indicative of breast cancer [70]. In nuclear medicine, small amounts of radioactive isotopes are used to create images of organs and tissues, providing functional information about the body’s physiology through diagnostic procedures like positron emission tomography (PET) and single-photon emission computed tomography (SPECT) [71] (Fig. 3). These procedures are generally quick, non-invasive, and offer valuable diagnostic insights. However, despite the relatively low doses used, this exposure can potentially cause cellular damage or increase the risk of cancer over time. It is therefore essential to carefully assess the frequency of diagnostic tests and IR doses used to manage and minimize the risk of potential harm [72, 73]. At the moment, unlike CT or X-Ray exposure, PET and SPECT do not have large-scale epidemiological studies linking them directly to increase cancer incidence.

Fig. 3.

IR in diagnostic imaging and therapy. Diagnostic and therapeutic application of Low and High doses of IR in clinical applications. PET, positron emission tomography; SPECT, single-photon emission computed tomography; IMRT, intensity-modulated IR therapy; SBRT, stereotactic body radiotherapy.

On the other hand, radiotherapy involves higher doses of IR aimed at destroying cancerous cells or shrinking tumors. Indeed, radiotherapy is a cornerstone in the treatment of various cancers, including lung [74, 75], breast [76], cervical [77], prostate [78] and colorectal cancers [79], often as part of a multi-modal approach, combined with surgery, chemotherapy, or immunotherapy to improve outcomes [80]. It is used in curative treatment, adjuvant therapy post-surgery, or in palliative care to alleviate symptoms in advanced cancer stages. In Europe, the cancers with the highest number of patients in radiotherapy departments are breast cancer, lung cancer, prostate cancer, head and neck cancer, and rectal cancer [81]. Advances in IR technology, such as intensity-modulated IR therapy (IMRT), stereotactic body radiotherapy (SBRT), and proton therapy, have significantly improved precision, enabling targeted IR delivery to tumors while minimizing exposure to surrounding healthy tissues [82]. However, despite the precision of modern radiotherapy techniques, the higher doses used can cause side effects, including damage to normal tissues, skin reactions, fatigue, or long-term effects such as secondary cancers [83, 84]. While the therapeutic benefits of radiotherapy are substantial, the potential risks necessitate careful monitoring and planning to balance efficacy with patient safety.

NRF2 is involved in cellular response to IR and promotes a pro-survival response in irradiated cells and tissues, both healthy and cancer ones, through ROS detoxification, supporting DNA repair and modulating cytokine responses [85]. Literature data show that the activation of NRF2 signaling, either through electrophilic modification of Keap1 or through deficiency in Keap1 expression, leads to a reduction in intracellular ROS levels, increased cell viability and resistance to treatments including radiotherapy, in almost healthy and tumor cells [30, 86, 87, 88] The involvement of NRF2 in protecting from IR damage was first demonstrated in a preclinical study using a lung cancer cell line carrying Keap1 gene mutation with consequent NRF2 hyperactivation. The authors showed that the constitutive overexpression of NRF2 leads to low intracellular ROS levels and IR-resistant cancer cell phenotype [89]. Importantly, shRNA-mediated reduction of NRF2 expression induces ROS generation and increases protein oxidation resulting in enhanced sensitivity to radiation-induced cell death [89]. Similar results were obtained in mouse embryo fibroblasts (MEF) with gain of NRF2 function (Keap1^-⁣/-) as well loss of NRF2 function (NRF2^-⁣/-). The Keap1^-⁣/- MEF cells with high antioxidant capacity and low endogenous ROS levels were shown to be resistant to ionizing radiation-induced cell death. On the contrary, NRF2^-⁣/- MEF with low antioxidant capacity and high endogenous ROS levels resulted in enhanced sensitivity to $\gamma$-irradiation, leading to decreased survival. Overall, the results from cancer cells and nontumorigenic MEF cells unequivocally establish that high levels of NRF2 confer resistance to radiotherapy [89].

Repeated pretreatment of human fibroblasts exposed to IR with sulforaphane (SFN), a natural substance present in cruciferous vegetables that activates NRF2 [90], has been demonstrated to protect fibroblasts from IR. This leads to reduced ROS levels, decreased DNA damage and increased cell survival [91]. In agreement, SFN treatment was unable to protect NRF2 knockout mouse embryonic fibroblasts, indicating that the sulforaphane-induced radioprotection was NRF2-dependent. Conversely, the use of RNA interference or pharmacological inhibition of NRF2 in these same cell types results in increased ROS production and a radiosensitive phenotype [91]. Similar results were obtained in colon cancer cells, with or without NRF2 knockdown with the CRISPR-Cas9 technology, treated with sulforaphane and chemotherapy. The results showed that SFN reduces cisplatin-induced cell death only in NRF2-proficient cells compared to NRF2-Cas9 cells. Mechanistically, the authors found that NRF2 activation protects NRF2-proficient cells from the drug-induced DNA damage and the apoptotic function of the unfolded protein response (UPR) [92], suggesting a common function of NRF2 in response to chemo- and radiotherapy.

In the study by McDonald and colleagues [88], the authors report that IR activates NRF2-ARE pathway but this occurs only after a significant delay of five days. This activation was detected in breast cancer cells, both with single doses of IR (2–8 Gy) and with clinically relevant daily dose fractions (0.5–4 Gy), and it was shown to be dose-dependent [88]. An important aspect is that no ARE activation was found in the 24 hours following IR exposure, even at high doses of up to 10 Gy. This suggests that the NRF2-ARE response to IR exposure is a second-tier antioxidant response, which is activated only a little later after exposure. Moreover, they observed that NRF2 activation prior to IR exposure does not improve the survival of cells or animals after irradiation, indicating that early activation of the pathway does not offer protection against IR damage under normal conditions. Conversely, the loss of NRF2 makes the cells significantly more radiosensitive, both in vitro and in vivo [88].

IR was also shown to activate NRF2 in a dose-dependent manner in non-small cell lung cancer (NSCLC) cells. RNAi-mediated reduction of NRF2 significantly increases endogenous ROS levels, and decreases the expression of NRF2 target genes, dampening Notch1 expression and inducing IR-induced cellular apoptosis. These authors conclude that the NRF2-mediated Notch signaling is an important determinant in radio-resistance of lung cancer cells [93].

Knockdown of NRF2 shows potential DNA damage after X-rays irradiation in lung cancers. The authors showed that NRF2 knockdown disrupts damaged DNA repair by inhibiting DNA-dependent protein kinase catalytic subunit and interfering with Rad51 expression, suggesting that NRF2 plays a critical role in the development of radio-resistance by upregulating DNA damage response via the mitogen-activated protein kinase (MAPK) pathway [94].

In a more recent study, the authors showed that NRF2^-⁣/- MEFs are more sensitive to spontaneous and to IR-induced transformation and that NRF2 deficiency increases IR-induced NF-$\kappa$B pro-inflammatory responses most robustly late after exposure. The tendency of NRF2 to restrain inflammation is also reflected in the reprogramming of tumor antigen-specific lymphocyte responses in mice where NRF2 knockout switches Th2 responses to Th1 polarity, suggesting that targeting NRF2, especially in those tumors that constitutively express it, is an appealing way to enhance the therapeutic benefit of radiation and immunotherapy [95].

Altogether, these data highlight the key role of NRF2 in cellular protection from the IR-induced damage and in pro-survival and radio-resistance in tumors.

Modulation of NRF2 activity through genetic or pharmacologic approaches, as described above [54, 92] significantly affects cellular and tissue injury caused by IR, including radiotherapy. Below are described the main NRF2 activating or inhibiting molecules that are used in pre-clinical studies given that at the moment there are not molecules approved for clinical use. NRF2 activators enhance resistance to IR-induced damage by increasing antioxidants and detoxifying enzymes, reducing oxidative stress and DNA damage, and improving cell survival [137]. NRF2 activation is a key mechanism for many chemopreventive agents, helping to prevent tumorigenesis, although an excessive NRF2 activation may protect tumor cells from radiotherapy, reducing treatment efficacy [138]. NRF2 activators include a variety of natural and synthetic compounds, including sulforaphane, curcumin, and seleno-hormetic molecules.

Sulforaphane is one of the most extensively studied natural compounds that targets the NRF2-Keap1 signaling pathway, recognized for its antioxidant, chemopreventive and antiproliferative properties [139]. Mathew and colleagues [91] demonstrated the radioprotective effect of sulforaphane in human skin fibroblasts. Through site-directed mutagenesis and mass spectrometry analysis, it was shown that sulforaphane can directly modify the critical cysteine residue at position 151 of Keap1, causing the activation of the NRF2-Keap1-ARE signaling pathway [140]. Curcumin is another extensively studied natural compound with many therapeutic properties, including antioxidant and anticancer activities [52, 53, 141, 142]. Notably, it was shown to act as a sensitizer for IR and chemotherapy in several human cancers, including prostate cancer, by oncogene mouse double minute2 (MDM2) downregulation [143] and colorectal cancer, by suppressing NF-$\kappa$B and NF-$\kappa$B-regulated gene products [144]. Khor and colleagues [145] showed that Curcumin exerts demethylating effects on the promoter region of NRF2, resulting in increased expression of NRF2 and its target genes. In addition, curcumin may indirectly phosphorylate NRF2 at serine- and/or threonine-rich regions, promoting its nuclear translocation. Furthermore, curcumin can directly interact with the cysteine thiol(s) groups of Keap1, reducing its inhibitory effect on NRF2 [146].

Seleno-hormetic compounds exhibit a broad spectrum of biological activities including anticancer and antiproliferative effects and modulate hormetic genes and antioxidant enzyme functions. Studies have demonstrated the redox-modulating and IR-protective properties of seleno-hormetic compounds showing that seleno-compounds protect against IR-induced toxicity activating NRF2 transcription factor and, consequently, upregulating the adaptive stress response to IR [147].

While several compounds that activate NRF2 have been identified, there are only a few agents recognized as NRF2 inhibitors with suitable pharmacokinetic properties for in vivo use [137]. Given the aberrant activation and the complex and varied role of NRF2 in cancer, these inhibitors are gaining interest as potential anticancer agents. Indeed, they might enhance the responsiveness of cancer cells to radio and chemotherapy and reduce chemo- and radio-resistance by downregulating the activity of enzymes responsible for detoxification and drug elimination through the inhibition of NRF2. However, NRF2 inhibitors might also increase damage to healthy tissues, causing side effects like inflammation and fibrosis [103, 115, 120, 121]. NRF2 inhibitors exert their activity at different levels depending on their characteristics: they can regulate NRF2 at the post-transcriptional level by degrading its mRNA or affecting NRF2 translation and post-translational regulation [147, 148]. They can block the translocation of NRF2 to the nucleus, or alter the binding between NRF2 and DNA [140, 149, 150]. NRF2 inhibitors can be identified in various classes of compounds, including flavonoids, natural compounds found in fruits, vegetables, and plants, with antioxidant, anti-inflammatory, and anticancer properties. While many flavonoids have been identified as NRF2 activators, some have exhibited inhibitory effects. For instance, in vivo studies have shown that luteolin reduces NRF2 mRNA and protein levels, sensitizing cells to anticancer drugs [151]. However, the effects of flavonoids on NRF2 activity are cell-type specific and concentration-dependent, and their application in cancer therapy requires further investigation. A known NRF2 inhibitor is brusatol, a natural compound extracted from the plant Brucea javanica [148]. Brusatol has been shown to reduce NRF2 protein levels by affecting NRF2 translation and post-translational regulation in various cell lines, and sensitizes A549 lung tumor cells to the anticancer drug cisplatin, both in vitro and in vivo [148, 152, 153]. However, the application of brusatol in humans has encountered challenges due to unresolved issues such as toxicity, transient nature of the reduction in NRF2 protein levels, and difficulties in drug delivery [152, 154]. Another interesting inhibitor of NRF2 is metformin (1,1-dimethylbiguanide hydrochloride), a drug used to treat type 2 diabetes and approved as an anticancer agent for certain tumors [155]. Metformin was shown to increase sensitivity to anticancer treatments by reducing NRF2 mRNA and protein levels through suppression of the rapidly accelerated fibrosarcoma (RAF)-ERK-NRF2 signaling pathway or induction of the microRNA-34a, which decreases NRF2 protein expression via the SIRT1/peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1$\alpha$)/NRF2 pathway [156]. However, given the complexity and variety of actions of this molecule, more research is needed to better understand its role in the NRF2 pathway and in modulating the response to anticancer treatments.

In conclusion, NRF2 modulation presents a promising yet complex therapeutic strategy, requiring a careful balance between protecting normal tissues and enhancing tumor response to treatment, particularly radiotherapy. Moreover, the double role of NRF2 in both carcinogenesis and tumor progression adds further complexity to its therapeutic targeting [157]. Therefore, the use of specific NRF2 activators or inhibitors in cancer therapy must be approached with prudence. It is also important to note that, at present, no NRF2-targeting molecules have been approved for medical use.

NRF2 plays a crucial role in the cellular response to IR used both in clinical diagnostic imaging and radiotherapy. While NRF2 activation offers protection against IR-induced oxidative damage in healthy tissues and helps prevent the onset of long-term damages, including malignant transformation, it may also promote tumor viability and resistance to radiation therapy. Inhibiting NRF2 represents an encouraging strategy to improve sensitivity of tumor cells to IR and the development of NRF2 inhibitors for clinical use as adjuncts to radiotherapy holds great potential. However, several challenges remain. One of the main obstacles is the selective targeting of NRF2 pathways in tumor cells without affecting normal tissues, which could increase the risk of side effects. Moreover, the potential for compensatory mechanisms in the cell, where other stress response pathways may take over when NRF2 is inhibited, must be carefully considered in the design of combination therapies. Further research is needed to better understand the precise role of NRF2 in IR responses and to identify the optimal timing and dosing strategies for NRF2 inhibition. Clinical trials assessing the safety and efficacy of NRF2 inhibitors, either alone or in combination with existing treatments, are essential to translating these findings into therapeutic practice.

AV and GD designed the outline, wrote the original draft, and reviewed the literature. Both authors contributed to editorial changes in the manuscript. Both authors read and approved the final manuscript. Both authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

Not applicable.

This work was supported by the institutional “Ricerca Corrente” granted by the Italian Ministry of Health.

The authors declare no conflict of interest. Given her role as the Guest Editor, Gabriella D’Orazi had no involvement in the peer-review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Alexandros G. Georgakilas and Graham Pawelec.